bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Altered levels of soluble markers of inflammation in people living with HIV on long term suppressive antiretroviral therapy

Hemalatha Babu[1,2], Anoop T Ambikan[2], Erin E Gabriel[3], Sara Svensson Akusjärvi[2], Alangudi Natarajan Palaniapan[6], Vijila Sundaraj[4], Naveen Reddy Mupanni[2], Maike Sperk[2], Narayanaiah Cheedarla[1], Rathinam Sridhar[4], Srikanth P Tripathy[1], Piotr Nowak[5], Luke Elizabeth Hanna[1*] , Ujjwal Neogi[2*]

[1]Department of HIV/AIDS, National Institute for Research in Tuberculosis, ICMR, Chennai, India

[2]Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

[3]Department of Medical Epidemiology and Biostatistics and Institute of Environmental Medicine both of Karolinska Institutet Stockholm, Sweden

[4]Government Hospital of Thoracic Medicine, Tambaram Sanatorium, Chennai, India

[5]Department of Medicine Huddinge, Unit of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

[6]Department of Clinic, National Institute for Research in Tuberculosis, ICMR, Chennai, India.

Running Title: Systemic inflammation following ART

***Correspondence:** Ujjwal Neogi, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, e-mail- ujjwal.neogi@ki.se, Phone: +46 852483680

Luke Elizabeth Hanna, Department of HIV/AIDS, National Institute for Research in Tuberculosis, ICMR, Chennai, India, e-mail- hannatrc@yahoo.com

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Abstract:

Objective(s): To assess the levels of systemic inflammatory markers of age-associated co-morbidities in people living with HIV (PLHIV) on long term suppressive antiretroviral therapy (ART).

Design: Prospective cross-sectional study in a well-defined Indian cohort of PLHIV.

Methods: Blood samples were obtained from therapy naïve PLHIV (Pre-ART, n=43), PLHIV on ART for >5 years (ART, n=53), and HIV-negative healthy controls (HIVNC, n=41). Samples were analyzed for 92 markers of inflammation, sCD14, sCD163, telomere length and HIV-1 reservoir.

Results: Despite a median duration of eight years of successful ART, sCD14 ($p<0.001$) and sCD163 ($p=0.04$) levels continued to be significantly elevated in ART group as compared to HIVNC. Besides, eleven inflammatory markers, including 4E-BP1, ADA, CCL23, CD5, CD8A, CST5, MMP1, NT3, SLAMF1, TRAIL and TRANCE, were found to be significantly different ($p<0.05$) between the groups. Many of these markers are associated with age-related co-morbidities including cardiovascular disease, neurocognitive decline and some of these markers are being reported for the first time in the context of HIV-induced inflammation. Linear regression analysis showed a significant negative association between HIV-1-positivity and telomere length ($p<0.0001$). in ART-group CXCL1 ($p=0.048$) and TGF-α ($p=0.026$) have a significant association with increased telomere length and IL-10RA was significantly associated with decreased telomere length ($p=0.042$).

Conclusions: The study identified several candidate biomarkers of age-related pre-mature aging in PLHIV on successful ART in a standardized public-health setting. This observation warrants further mechanistic studies to generate evidence to highlight the need for enhanced treatment monitoring and special interventions in HIV-infected individuals.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Word Count:

Abstract: 247

Body: 3457

Figures: 3

Tables: 1

Funding: The Swedish Research Council, Swedish Physicians against AIDS, and Jeanssons Stiftelser.

Keywords: Inflamm-aging, HIV-1 reservoir, cART, LMIC

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Introduction

The most remarkable achievement in the battle against the Human Immunodeficiency Virus (HIV) is the discovery of very efficient, well-tolerated combinational antiretroviral therapy (ART), that has transformed the deadly viral infection into a chronic, manageable disease. In the absence of a cure, HIV-infection requires lifelong treatment. Though treatment successfully controls HIV-replication and prevents opportunistic infections, HIV-infected persons on long term ART not only succumb to death at an earlier age than the HIV-uninfected counterparts but also suffer from some maladies that are typically associated with human aging [1]. The effcet of HIV-associated inflammation and immune activation on premature onset of immunosenescence despite effective viral suppresion are thought to be the primary reasons for early aging in people living with HIV (PLHIV) [2].

Chronic, low-grade systemic inflammation resulting from an increased pro-inflammatory state contributes to the progressive pathophysiological changes associated with aging. This process of increase in pro-inflammation followed by a chronic inflammatory state is termed as "inflamm-aging" and is a significant risk factor for morbidity and mortality in the elderly people [3]. The inflammatory environment triggers the development of several age-related noninfectious comorbidities (NICMs) [1]. In HIV infection, it is believed that viral persistence in a rare population of long-lived, latently infected cells despite successful ART contributes to the chronic inflammatory state [1].

Unlike in high-income countries (HIC), the ART program in low- and middle-income countries (LMIC) like India, follows a public health approach with a standardized regimen for all PLHIV. As of December 2016, nearly one million PLHIV were receiving free ART through the government program in the country [4]. The recommended first-line ART regimen includes one non-nucleoside reverse transcriptase inhibitor (NNRTI), either nevirapine (NVP) or efavirenz (EFV), in the backbone of two nucleoside reverse transcriptase

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

inhibitors (NRTI), either zidovudine (AZT) or tenofovir (TDF), and lamivudine (3TC) [5]. Although perfect adherence to treatment remains a challenge, the reasonably good response to first-line therapy indicates the overall success of the ART program in the country [6]. Thus, with the expansion of the ART program and its consequences in PLHIV, the burden of age-related non-AIDS diseases are likely to increase. Since the environment has an enormous impact on age and age-related diseases, and the genetic determinants of aging may vary across populations, studies conducted in HICs might not apply to the LMICs [7].

The present study attempted to evaluate HIV-associated inflammation and immune activation and the contribution to Inflamm-aging in PLHIV on long-term combination ART (cART) by assessing markers of inflammation as well as aging, including a panel of 92 inflammatory markers, two well-characterized immune activation markers (sCD14 and sCD163), and telomere length. The study provides useful insights into the role of inflammation and aging in HIV-1 infected individuals despite successful ART.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Methods

Study design and participants

The study included three groups of individuals: i) treatment-naïve PLHIV with viremia and moderate CD4 count (Pre-ART herein) ii) PLHIV of aged between 35-60 years on ART for more than five years with suppressed viremia on national first-line ART and >90% adherence to treatment (ART herein), and iii) life-style, age and gender-matched (with ART group) HIV-1 negative healthy individuals free of any kind of chronic illness (HIVNC herein). The HIV-1 positive cohort was recruited from a tertiary care ART Centre at the Government Hospital for Thoracic Medicine (GHTM), Chennai, India, at the time of routine standard-of-care hospital visit. Exclusion criteria were pregnancy in women, Immune Reconstitution Inflammatory Syndrome (IRIS), presence of co-infections like active tuberculosis or hepatitis virus infection, history of co-morbidities like diabetes mellitus, obesity, evidence of cardiovascular disease or any chronic illness, illicit drug usage, alcohol consumption, and intake of anti-inflammatory drugs in the past one month. For the ART group, we screened 258 individuals, and recruited 55 persons who matched the above criteria for the study. After screening 166 individuals for the pre-ART group, 41 who met the eligibility criteria were recruited for the study. Plasma viral load was measured using the *Abbott* RealTime HIV-1 viral load assay (Abbott, US). Two individuals in the ART group had viral load >150 copies/mL (4000 and 1800 copies/mL, respectively) and had to be excluded from the study. We screened 295 healthy individuals in and around Chennai, India, and identified 43 life-style, age and gender-matched individuals for the HIVNC group.

The overall study design is presented in Figure 1. After first-time counseling and obtaining informed consent to participate in the study, 15 mL of venous blood was collected from each study participant.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Proteomic profiling of the soluble factors in plasma

Plasma samples from the Pre-ART, ART and HIVNC groups were subjected to soluble proteome analysis using the Olink® Inflammation Panel that includes 92 inflammation-related soluble factors (Olink Bioscience AB, Uppsala, Sweden) [8]. We measured 92 markers of inflammation in the plasma samples of the three study groups. Of the 92 proteins, only 75 were detectable in >50% of the samples, and therefore our analysis was restricted to these proteins alone. Two Pre-ART samples and one HIVNC sample did not pass the quality control and had to be excluded from our analysis. We also measured two widely reported biomarkers of immune activation, sCD14 (Human CD14 Quantikine ELISA Kit R&D Systems, UK) and sCD163 (Thermo Scientific™ Pierce™ Human CD163 Kit, Thermo Scientific, USA) in plasma.

Telomere length in peripheral blood mononuclear cells (PBMC)

As a molecular biomarker of "biological aging", the leucocyte telomere length was measured in PLHIV on ART and HIV-negative controls. Genomic DNA was extracted from PBMC using the QIAamp *DNA Mini Kit (Qiagen, Germany).* and telomere length was measured using the Absolute Human Telomere Length Quantification qPCRAssay Kit (AHTLQ; ScienCell Research Laboratories, US) following manufacturer's instructions. All samples were tested in triplicate.

Total HIV-1 DNA quantification using IC-qPCR marker for HIV-1 reservoir level

To quantify total HIV-1 DNA from PBMC, internally controlled qPCR (IC-qPCR) was performed as described previously [9]. IC-qPCR was performed in duplicate using 500ng template DNA and Takara Premix Ex Taq™ (Probe qPCR) (Takara, Japan). Primers targeting HIV-1 LTR and Beta-globulin were used. Total HIV-1 DNA copy numbers was calculated based on the linear equation of the 10-fold Beta-globulin standard curve derived from Jurkat

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

cells and the 10-fold pNL4-3 plasmid standard curve, diluted in 50 ng/µL of Jurkat DNA to mimic clinical samples, and normalized to obtain HIV-1 DNA copies per million PBMC.

Statistical analysis and data visualization

Mann Whitney U test, Chi-square test, and one-way analysis of variance (ANOVA) were performed to investigate difference in mean levels of protein expression (NPx) in the different groups under study. Multivariate linear regression for the outcome of telomere length was used to investigate the association between HIV status and HIV treatment duration adjusting for chronological age as well as other disease and patient characteristics. These same models were used to investigate evidence of mediation of the HIV-telomere relationship by soluble biomarkers. A heatmap was generated to visualize the clustering of samples based on protein expression using *gplots* v3.0.1 in R. Similarity in protein expression within the groups was visualized using a multi-dimensional scaling plot (MDS) in R package, edge R. All other analysis was performed using base R. P-values are not corrected for multiple comparisons, although false discovery rate was used in some of the biomarker discovery analyses.

Ethical Clearances

The study was approved by the Institutional Ethics Committee of the National Institute for Research in Tuberculosis (NIRT IEC No: 2015023) and Institutional Review Board of the Government Hospital for Thoracic Medicine (GHTM-27102015) Chennai, India. All the study participants gave written informed consent. Patient identities were anonymized and delinked before analysis.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Results

Patient characteristics

Cohort characteristics are presented in Table 1. All three cohorts were gender matched. There were 51%, 43% and 51% of females in the Pre-ART, ART and HIVNC respectively. The median age of ART, Pre-ART and HIVNC groups were 45, 40 and 46 years respectively. In the ART group, the median (IQR) duration of treatment was 8 years (6-10 years). As per the inclusion criteria, all the patients had >90% of self-reported adherence which was further confirmed by viral load <150 copies/mL and very low-level HIV-1 reservoir with median (25th -75th) 2.87 (2.62-3.18) $\log_{10}$ copies/10^6 PBMC. Within the ART group, 57% (30/53) were on a zidovudine, lamivudine and nevirapine (ZDV/3TC/NVP) regimen and the remaining 43% (23/53) were on a tenofovir, lamivudine, and efavirenz (TDF/3TC/EFV) regimen. All individuals were initiated on antiretroviral treatment in the chronic phase of disease with a median (25th -75th) CD4 count of 186 (100-280) cells/µL, as per the National guidelines for eligibility to ART existing at that point in time.

Soluble markers of immune activation in plasma

Soluble markers of immune activation, sCD14 and sCD163, were measured in plasma samples of the three study groups. PLHIV had significantly higher levels of sCD14 (**Figure 2a**) and sCD163 (**Figure 2b**) in plasma as compared to HIVNC ($p<0.001$, Mann Whitney U Test). Interestingly, despite prolonged suppressive ART (median duration of eight years of cART), there was no significant decline in the levels of sCD14 in PLHIV. Levels of sCD163 were significantly lower in the ART group as compared to the Pre-ART group (30014 pg/mL vs. 68192 pg/mL, $p<0.001$, Mann Whitney U Test), but were significantly higher as compared to the HIVNC group ($p=0.04$, Mann Whitney U Test). We did not find any significant correlation between duration of cART and sCD14 (Spearman r: 0.163; $p=0.2432$) or sCD163 (Spearman r: 0.154; $p=0.2720$) levels in the ART group.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Soluble markers of inflammation in plasma

To identify candidate biomarkers for future study, we looked for biomarkers that differed significantly between the groups by Random Forest (RF) analysis (**Figure 3a**). The proteins with the most significant differences were TNFRSF9, sCD6, sCD5, TRANCE, and CXCL9. Hierarchical clustering analysis (HCA) with false discovery rate (FDR) <0.001, revealed clustering of 79% (31/39) of the Pre-ART samples along with two samples from the HIVNC and one from ART groups **(Figure 3b)**. Seven Pre-ART samples clustered with the HIVNC and ART groups. The HCA result was consistent with that of the MDS plot (**Supplementary Fig 1**) and principal component analysis.

Among the 75 proteins, 41 showed a significant difference ($p<0.05$, Tukey HSD) between at least one of the groups compared (ART vs Pre-ART, Pre-ART vs HIVNC and ART vs HIVNC) (**Supplimentary table 1**). Levels of 31 inflammatory proteins were found to be significantly different between the Pre-ART and HIVNC groups, 38 proteins were significantly different between the Pre-ART and ART groups, and 11 proteins were significantly different ($p<0.01$, Tukey HSD) between the HIVNC and ART groups (**Figure 3c**). Out of 11 proteins, 4E-BP1 was found to differ significantly only between the ART and HIVNC groups, and not between any of the other groups. Five proteins were different between all the three groups (CD8A, TRANCE, sCD5, SLAMF1, and CCL23) (**Figure 3c**). Of the proteins that showed significant difference between the ART and HIVNC groups, levels of soluble NT3, CD5, TRAIL, and TRANCE were lower, but levels of ADA, MMP1, CST5 and 4E-BP1 were higher, when compared to both HIVNC and Pre-ART groups. On the other hand, CD8A, SLAMF1 and CCL23 were higher in the ART group as compared to the HIVNC group (**Figure 3d**).

Telomere Length

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Telomere length was analyzed only in two groups (HIVNC and ART) as PBMC were not available for the Pre-ART group. Linear regression analysis, after adjusting for chronological age and gender showed a significant negative association of HIV-1 positive status on telomere length (-2.84, 95%CI -4.012, -1.67, $p<0.0001$) with the ART group having significantly shorter telomeres. However, no significant association was observed between duration of treatment and telomere length after adjusting for age and markers of disease progression within the ART group. Several of the biomarkers considered were significantly associated with telomere length after adjustment for age, HIV status, and gender, these include CXCL1 and CD40 which are both weakly positively association with telomere length, MMP-10 and CX3CL1, which are positively associated with telomere length and OSM which is negatively associated; results are outlined in detail in supplementary Table 2. Within the ART group, after adjusting for age, gender, duration of treatment, HIV-1 reservoir, CD4 count at initiation, CD8/CD4 ratio and sCD14, we observed CXCL1 and TGF-α to have a significant association with increased telomere length (0.2905, 95%CI: 0.0029,0.5780 $p=0.048$) and (0.7865, 95%CI:0.1003,1.4727, $p=0.026$), respectively. We also found that IL-10RA was significantly associated with decreased telomere length (-1.79, 95%CI: -3.51, -0.07 $p=0.042$)

Discussion

This study examined a cohort of PLHIV on long-term successful cART from India, and found that despite a median duration of eight years of suppressive cART, several soluble inflammatory markers that were found to be evaluated in HIV-1 infected untreated subjects, were also significantly elevated in the ART group as compared to the HIVNC group. This study found higher levels of the inflammatory protein CST5, a first in PLHIV, as compared to HIVNC, in addition to higher levels of 4E-BP1, SLAMF1, CCL23 and lower levels of NT3 proteins, a first in PLHIV on long term cART.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

It has been reported that certain age-related NICMs like diabetes mellitus, cardiovascular disease, cancer, bone fracture and renal failure, are more common among HIV-1 infected individuals as compared to the general population. Exposure to prolonged cART along with low grade inflammation and persistent immune activation seen in HIV-infection is thought to be the cause for the increased risk of NICMs [2, 10]. Chronic inflammatory conditions and persistent immune activation are believed to be the major drivers of aging physiology. Inflammatory biomarkers of aging and their association with co-morbid diseases has been studied well in many elderly populations. Proteins like 4E-BP1 and association of mTOR with aging and age-related diseases [11, 12], has already been documented. However, there are no studies that have examined the response of plasma 4E-BP1 to ART. We found higher levels of 4E-BP1 in the ART group as compared to both HIVNC and the Pre-ART group, suggesting this marker may be associated with duration of HIV infection and/or exposure to anti-retroviral drugs.

In the case of well-studied immune activation markers, the ART group had significantly higher levels of sCD14 like that seen in the Pre-ART group. Contradictory results that have been reported from different studies on the effect of cART on sCD14 [13-15] due to a variety of contributors [16, 17]. On the other hand, sCD163, a marker of vascular inflammation [18] and neurocognitive impairment [19], was higher in PLHIV than in healthy controls, which is in contrast to previous reports [20]. The novelty of our study was to explore of a large panel of inflammatory markers and show significantly higher levels of MMP1 [21], ADA [22], CD8A [23], SLAMF1 [24] and CCL23 [25] in PLHIV on long term ART. Many of these markers have been reported to be linked with early stages of various age-related diseases.

sCD5 and TRAIL have been reported as biomarkers of inflammation and related diseases in both HIV-infected as well as uninfected individuals [26-28]. We found lower levels of sCD5 and TRAIL in the ART group as compared to the HIVNC group. Of particular mention is the

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

association between lower plasma and cerebrospinal fluid levels of TRAIL and early Alzheimer Disease (AD) [29]. CD5, a negative regulator of antigen receptor signal transduction in lymphocytes [30], is reported to stimulate the production of the anti-inflammatory cytokine IL-10 by B-cells [31]. Low levels of sCD5 in HIV-infected individuals, associated with the existing pro-inflammatory state could promote the development of age-related cancers and other diseases in these individuals. An earlier study conducted in a Swedish cohort reported normalization of sCD5 to a healthy state upon anti-HIV treatment [32], which is in contrast to our findings. However, the Swedish cohort was on two decades long successful therapy and were initiated on ART in the early stages of HIV-infection, unlike our cohort which was started on ART only in stage 2 or 3 of the disease as per national guidelines and policies available then.

TRANCE/RANKL, an important regulator of bone metabolism, was found to be lower in the ART group than in HIVNC. There is existing literature to show that HIV-infected individuals treated with NRTIs and NNRTIs have lower than normal levels of circulating RANKL [33]. Lower levels of TRANCE have been reported as an independent predictor of non-traumatic fracture indicating its effect on osteoclastogenesis [34]. Though Cystatin D (CST5) has not been well studied in HIV, our study showed altered levels of this protein in HIV-1 infected individuals. To the best of our knowledge this is the first study reporting elevated levels of CST5 in HIV infection.

NT3, another inflammatory marker, is reported to be strongly associated with neurocognitive impairment in PLHIV [35, 36] and MMP1 with senescence associated conditions [37, 38]. Higher levels of these two proteins could be due to a favoring age-associated changes and premature aging in HIV-infected individuals with prolonged exposure to cART. The decreased expression of NT3 was also observed in colorectal cancer [39], while increased levels of plasma MMP1 have been associated with coronary atherosclerosis [40] and cancers

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

[41, 42] further provide evidence to support the role of these proteins in disease development during aging.

Higher levels of CCL23 and SLAMF1, which are involved in monocyte activation, in the ART group could contribute to sustained release of sCD14 [43]. Further, continued immune activation could be due to several other mechanisms including, sustained HIV-replication in reservoir sites like lymph nodes and gastrointestinal tract [44], low levels of HIV and its proteins [45, 46], altered gut microbiota in PLHIV [47] and different ART regimens [48].

Telomere length (TL) is a marker of replicative senescence and is a well-known predictor of health outcome in aging populations. Chronic inflammation can potentially contribute to age-related diseases through increased production of reactive oxygen species that damage telomeres and lead to cellular and immunological senescence [49]. Several studies have noticed an association between TL and age-related diseases [50]. In HIV infection, immune activation and expanded proliferation of leukocyte subsets immediately after infection, along with uncontrolled viremia have been associated with a rapid decrease in TL [51], followed by increase in TL with ART initiation. However, telomere induced replicative senscence with long term ART has also been reported [52]. Our study also found shorter telomeres in PLHIV on ART for >5 years and noticed a significant association between TL and inflammatory markers like CXCL1, TGF-α and IL10RA. Telomere length shortening has been well reported in several inflammatory conditions and related diseases like cancer. Zadka et al (2018) showed a positive correlation between IL10RA expression and disease pathogenesis in colorectal cancer [53].

Our study has some limitations that merit comment. First, the HIV-infected population selected for this study were from the best pool of successfully treated individuals (free of co-infections and co-morbidities), through the Indian National ART program. The findings may not generalize to the general population of treated HIV-1 positive individuals. Second, due to

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

the lack of earlier studies in this setting, the design of our study, and limited sample size, the conclusions drawn are limited to associations with modest significance. Also, many the statistical tests were run, but only the most significant results have been highlighted, for this reason, the results should be considered hypothesis generating. Third, the patients were not monitored virologically as a standard of care, and we only have virological data at the time of sampling. Any potential viral blips which are most unlikely reflected by the patients CD4 history could have introduced bias in the expression of inflammatory markers. However, among the few studies involving inflammatory markers in virally suppressed populations from LMICs [54, 55], our study is the first comprehensive study on inflammation and aging, that compared a large panel of inflammatory markers in PLHIV on long term suppressive ART from India, which uses a standardized public health approach for treatment monitoring. Finally, the telomere length comparison between the ART group and the HIVNC could not be adjusted for health factors or disease progression markers, such as CD4 as these were not measured on HIVNC. As Telomere length was taken as the average for PBMCs, the different in CD4 and CD8 cells percentages may have contributed to the magnitude of the difference; further studies investigating difference based on cell type are needed.

In conclusion, we observed several soluble inflammatory biomarkers that differed significantly between PLHIV and healthy individuals, despite eight years of successful therapy- Interestingly, several of these biomarkers have been previously shown to be associated with inflammatory conditions like cancer, cardiovascular, neurological and skeletal diseases. Put together, these data suggest that HIV-1 infected individuals, even those on long term successful ART, may be at higher risk of developing inflammatory diseases leading to inflamm-aging, a low-grade chronic inflammation which is a major risk factor for the development of many age-associated diseases and to some extent morbidity and mortality in elderly people in the general population. In addition, we found a large difference in telomere

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

length between subjects on long-term ART and HIVNC subjects, even after adjusting of age; this warrants further investigation.

Funding sources

This work was supported by grants from the Swedish Research Council Establishment Grant [2017-01330 (U.N.), 2017-01898 (E.E.G)], Swedish Research Council (Interdisciplinary-2018-06156) (U.N.) Swedish Physicians Against AIDS Foundation (FOb20170004) (UN), and Jeanssons Stiftelser (JS2016–0185) (U.N.).

Acknowledgments

H.B. acknowledge support from the HIV Research Trust, UK supported in part by ViiV Health Care, Council of Scientific and Industrial Research (CSIR), India. Authors would like to thank technical support received from Mrs. Gomathi, Mr. Kannan Muthuramalingam, and Mr. Sathya Murthi.

Conflict-of-interest disclosure

The authors declare no competing financial interests

Contribution: H.B., S.S.A, N.R.M, M.S., N.C. performed the laboratory experiments; A.T.A. and E.E.G. performed bioinformatics and statistical analysis; U.N. and A.T.A. made the figures. N.P., R.S., V.J., and S.K.T. recruited study subjects and provided the clinical data. P.N. provided the clinical interpretation. U.N. and L.E.H conceived and designed the study; U.N. wrote the first draft of the paper reviewed by E.E.G, H.B., M.S., L.E.H. All the authors approved the final version of the manuscript.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure Legends:

Figure 1. Flow diagram of study design and experimental plan: 424 HIV-1 positive individuals and 295 HIV-1 negative healthy controls were screened. Following defined inclusion and exclusion criteria, 43 healthy controls, and 53 HIV positive ART-experienced subjects and 41 ART-naïve HIV-1 positive subject were recruited for the study. The methodology used for the study was also presented.

Figure 2. Plasma immune activation markers: Soluble CD14 (a) and CD163 (b) in plasma of the three groups of individuals were measured using ELISA.

Figure 3. Plasma inflammation markers: (a) The RF analysis of soluble factors resulted in predictive accuracies of 86.6% for HIVNC, Pre-ART and ART. The soluble factors importance plots displays top 30 metabolites which most strongly contribute to the groups' separation for HIVNC, Pre-ART and ART. (b) Hierarchical clustering analysis of ANOVA of differentially expressed proteins with false discovery rate (FDR) <0.001, identified clustering of 79% (31/39) of Pre-ART samples along with two samples from the HIVNC and one from the ART group. The ART and HIVNC samples clustered separately from Pre-ART samples but intermingled with each other. (c) Venn diagram showing significantly different protein in the study group. The sum of the numbers in each large circle represents the total number of differentially expressed proteins in plasma in the different groups (HIVNC vs. ART, Pre-ART vs.ART and Pre-ART vs. HIVNC). The overlapping part of the circles represents significantly different proteins in the indicated groups. (d) Comparative analysis of 11 soluble markers that are significantly different between ART and HIVNC.

Table Legends:

Table 1. Patients' demographic and clinical parameter

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

References:

1. Deeks SG. **HIV infection, inflammation, immunosenescence, and aging**. *Annu Rev Med* 2011; 62:141-155.

2. Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. **HIV as a Cause of Immune Activation and Immunosenescence**. *Mediators Inflamm* 2017; 2017:6825493.

3. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. **Inflamm-aging. An evolutionary perspective on immunosenescence**. *Ann N Y Acad Sci* 2000; 908:244-254.

4. UNAIDS. **Country Report: India**. In; 2016.

5. **Antiretroviral therapy guidelines for HIV-infected adults and adolescents: May 2013**. In. Edited by Department of AIDS Control NACO, Ministry of Health and Family welfare, Government of India. New Delhi.

6. Neogi U, Heylen E, Shet A, Chandy S, Shamsunder R, Sonnerborg A, et al. **Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study**. *PLoS One* 2013; 8(1):e55421.

7. Hoffman JM, Lyu Y, Pletcher SD, Promislow DEL. **Proteomics and metabolomics in ageing research: from biomarkers to systems biology**. *Essays Biochem* 2017; 61(3):379-388.

8. Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, et al. **Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability**. *PLoS One* 2014; 9(4):e95192.

9. Vicenti I, Meini G, Saladini F, Giannini A, Boccuto A, Schiaroli E, et al. **Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood**. *Clin Chem Lab Med* 2018; 56(3):e75-e77.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

10. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. **Premature age-related comorbidities among HIV-infected persons compared with the general population**. *Clin Infect Dis* 2011; 53(11):1120-1126.

11. Johnson SC, Rabinovitch PS, Kaeberlein M. **mTOR is a key modulator of ageing and age-related disease**. *Nature* 2013; 493(7432):338-345.

12. Oka SI, Hirata T, Suzuki W, Naito D, Chen Y, Chin A, et al. **Thioredoxin-1 maintains mechanistic target of rapamycin (mTOR) function during oxidative stress in cardiomyocytes**. *J Biol Chem* 2017; 292(46):18988-19000.

13. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. **Plasma levels of soluble CD14 independently predict mortality in HIV infection**. *J Infect Dis* 2011; 203(6):780-790.

14. Hattab S, Guiguet M, Carcelain G, Fourati S, Guihot A, Autran B, et al. **Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy**. *HIV Med* 2015; 16(9):553-562.

15. van den Dries L, Claassen MAA, Groothuismink ZMA, van Gorp E, Boonstra A. **Immune activation in prolonged cART-suppressed HIV patients is comparable to that of healthy controls**. *Virology* 2017; 509:133-139.

16. Dandona L, Dandona R, Kumar GA, Shukla DK, Paul VK, Balakrishnan K, et al. **Nations within a nation: variations in epidemiological transition across the states of India, 1990-2016 in the Global Burden of Disease Study**. *Lancet* 2017; 390(10111):2437-2460.

17. Mudd JC, Brenchley JM. **Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression**. *J Infect Dis* 2016; 214 Suppl 2:S58-66.

18. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. **Arterial inflammation in patients with HIV**. *Jama* 2012; 308(4):379-386.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

19. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. **Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection**. *Aids* 2013; 27(9):1387-1395.

20. Castley A, Berry C, French M, Fernandez S, Krueger R, Nolan D. **Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?** *PLoS One* 2014; 9(12):e115226.

21. Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC. **Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-kappaB**. *PLoS One* 2012; 7(8):e42507.

22. Climent N, Martinez-Navio JM, Gil C, Garcia F, Rovira C, Hurtado C, et al. **Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV**. *Immunol Cell Biol* 2009; 87(8):634-639.

23. Nishanian P, Hofmann B, Wang Y, Jackson AL, Detels R, Fahey JL. **Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease**. *Aids* 1991; 5(7):805-812.

24. Farina C, Theil D, Semlinger B, Hohlfeld R, Meinl E. **Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines**. *Int Immunol* 2004; 16(6):799-809.

25. Nardelli B, Tiffany HL, Bong GW, Yourey PA, Morahan DK, Li Y, et al. **Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1**. *J Immunol* 1999; 162(1):435-444.

26. Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, et al. **TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells**. *Blood* 2005; 105(6):2458-2464.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

27. Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, et al. **Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults**. *Atherosclerosis* 2011; 215(2):452-458.

28. Balestrieri E, Grelli S, Matteucci C, Minutolo A, d'Ettorre G, Di Sora F, et al. **Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy**. *J Med Virol* 2007; 79(2):111-117.

29. Wu YY, Hsu JL, Wang HC, Wu SJ, Hong CJ, Cheng IH. **Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer's Disease**. *Dement Geriatr Cogn Dis Extra* 2015; 5(3):424-434.

30. Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. **CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1**. *Mol Cell Biol* 1999; 19(4):2903-2912.

31. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. **Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production**. *Blood* 2002; 100(13):4537-4543.

32. Sperk M, Zhang W, Nowak P, Neogi U. **Plasma soluble factor following two decades prolonged suppressive antiretroviral therapy in HIV-1-positive males: A cross-sectional study**. *Medicine (Baltimore)* 2018; 97(5):e9759.

33. Mora S, Zamproni I, Cafarelli L, Giacomet V, Erba P, Zuccotti G, et al. **Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents**. *Aids* 2007; 21(9):1129-1135.

34. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, et al. **Soluble RANKL and risk of nontraumatic fracture**. *Jama* 2004; 291(9):1108-1113.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

35. Bergman E, Ulfhake B, Fundin BT. **Regulation of NGF-family ligands and receptors in adulthood and senescence: correlation to degenerative and regenerative changes in cutaneous innervation**. *Eur J Neurosci* 2000; 12(8):2694-2706.

36. Meeker RB, Poulton W, Markovic-Plese S, Hall C, Robertson K. **Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection**. *J Neurovirol* 2011; 17(3):258-273.

37. Lei LT, Chen JB, Zhao YL, Yang SP, He L. **Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1**. *Eur Rev Med Pharmacol Sci* 2016; 20(6):1203-1213.

38. Benanti JA, Williams DK, Robinson KL, Ozer HL, Galloway DA. **Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1**. *Mol Cell Biol* 2002; 22(21):7385-7397.

39. Genevois AL, Ichim G, Coissieux MM, Lambert MP, Lavial F, Goldschneider D, et al. **Dependence receptor TrkC is a putative colon cancer tumor suppressor**. *Proc Natl Acad Sci U S A* 2013; 110(8):3017-3022.

40. Castillo L, Rohatgi A, Ayers CR, Owens AW, Das SR, Khera A, et al. **Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study**. *J Interferon Cytokine Res* 2010; 30(5):339-347.

41. Warnecke-Eberz U, Metzger R, Holscher AH, Drebber U, Bollschweiler E. **Diagnostic marker signature for esophageal cancer from transcriptome analysis**. *Tumour Biol* 2016; 37(5):6349-6358.

42. Huang Z, Yang Q, Huang Z. **Identification of Critical Genes and Five Prognostic Biomarkers Associated with Colorectal Cancer**. *Med Sci Monit* 2018; 24:4625-4633.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

43. Theil D, Farina C, Meinl E. **Differential expression of CD150 (SLAM) on monocytes and macrophages in chronic inflammatory contexts: abundant in Crohn's disease, but not in multiple sclerosis**. *J Clin Pathol* 2005; 58(1):110-111.

44. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, et al. **HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir**. *J Clin Invest* 2005; 115(11):3250-3255.

45. Meier A, Alter G, Frahm N, Sidhu H, Li B, Bagchi A, et al. **MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands**. *J Virol* 2007; 81(15):8180-8191.

46. Anand AR, Rachel G, Parthasarathy D. **HIV Proteins and Endothelial Dysfunction: Implications in Cardiovascular Disease**. *Front Cardiovasc Med* 2018; 5:185.

47. Sessa L, Reddel S, Manno E, Quagliariello A, Cotugno N, Del Chierico F, et al. **Distinct gut microbiota profile in antiretroviral therapy-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers**. *Aids* 2019; 33(6):1001-1011.

48. Hileman CO, Funderburg NT. **Inflammation, Immune Activation, and Antiretroviral Therapy in HIV**. *Curr HIV/AIDS Rep* 2017; 14(3):93-100.

49. Jurk D, Wilson C, Passos JF, Oakley F, Correia-Melo C, Greaves L, et al. **Chronic inflammation induces telomere dysfunction and accelerates ageing in mice**. *Nat Commun* 2014; 2:4172.

50. Rizvi S, Raza ST, Mahdi F. **Telomere length variations in aging and age-related diseases**. *Curr Aging Sci* 2014; 7(3):161-167.

51. Pathai S, Lawn SD, Gilbert CE, McGuinness D, McGlynn L, Weiss HA, et al. **Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study**. *Aids* 2013; 27(15):2375-2384.

bioRxiv preprint doi: https://doi.org/10.1101/418012; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

52. Cobos Jimenez V, Wit FW, Joerink M, Maurer I, Harskamp AM, Schouten J, et al. **T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment**. *J Infect Dis* 2016; 214(2):216-225.

53. Zadka L, Kulus MJ, Kurnol K, Piotrowska A, Glatzel-Plucinska N, Jurek T, et al. **The expression of IL10RA in colorectal cancer and its correlation with the proliferation index and the clinical stage of the disease**. *Cytokine* 2018; 110:116-125.

54. Margolick JB, Bream JH, Nilles TL, Li H, Langan SJ, Deng S, et al. **Relationship Between T-Cell Responses to CMV, Markers of Inflammation, and Frailty in HIV-uninfected and HIV-infected Men in the Multicenter AIDS Cohort Study**. *J Infect Dis* 2018; 218(2):249-258.

55. Margolick JB, Bream JH, Martinez-Maza O, Lopez J, Li X, Phair JP, et al. **Frailty and Circulating Markers of Inflammation in HIV+ and HIV- Men in the Multicenter AIDS Cohort Study**. *J Acquir Immune Defic Syndr* 2017; 74(4):407-417.

Cross-sectional Study

Screening (2015-2018)

PLHIV not on ART
(Pre-ART)
n=166

PLHIV on ART
(ART)
n=258

HIV-negative Controls
(HIVNC)
n=295

life-style matched

Inclusion criteria

All three cohorts : Aged between 35-60 years
ART cohort : Treatment on National first line therapy >5 years
Self reported adherence >90%
Stable CD4 count for past two years
Viral load <150 copies/mL
Pre-ART cohort : CD4 T-cell count >250 cells/mm^3

Exclusion criteria (all three cohorts)

Pregnancy in women,
Presence of co-infections (active tuberculosis or hepatitis virus infection)
History of co-morbidities (diabetes mellitus, any other chronic illness)
Evidence of cardiovascular diseases
Illicit drug usage and alcohol consumption,
Intake of anti-inflammatory drugs

Study Cohorts

PLHIV not on ART
(Pre-ART)
n=41

PLHIV on ART
(ART)
n=53

HIV-negative Controls
(HIVNC)
n=43

Laboratory Experiments

Olink® Inflammation panel

Immuno reaction Extension reaction Amplification Detection and Analysis



Immune-activation Markers



sCD14 and sCD163

R&D Systems
Invitrogen

Telomere Length

ScienCell™ Research Lab Inc.

Internally controlled total HIV-1 DNA quantitative PCR (IC-qPCR)



Vicenti et al Clin Chem Lab Med 2018


a.
p<0.001
p<0.001
ns
sCD14 (Log10 pg/mL)
6.5
6.3
6.1
HIVNC
Pre-ART
ART
b.
p<0.001
p<0.001
p=0.037
sCD163 (Log10 pg/mL)
5.5
5.0
4.5
4.0
3.5
3.0
2.5
HIVNC
Pre-ART
ART
Group
HIVNC
PreART
ART


a.
HIVNC vs. Pre-ART vs. ART
Increasing Importance to Group Separation
TNFRSF9 (Q07011)
CD6 (Q8WWJ7)
CD5 (P06127)
TRANCE (O14788)
CXCL9 (Q07325)
CD8A (P01732)
ADA (P00813)
NT-3 (P20783)
CXCL10 (P02778)
CCL19 (Q99731)
CASP-8 (Q14790)
CCL23 (P55773)
CXCL11 (O14625)
CD244 (Q9BZW8)
IL18 (Q14116)
IL10 (P22301)
4E-BP1 (Q13541)
IL-12B (P29460)
SCF (P21583)
IL-10RA (Q13651)
MMP-1 (P03956)
TRAIL (P50591)
SLAMF1 (Q13291)
MCP-3 (P80098)
LAP-TGF-β1 (P01137)
CCL4 (P13236)
STAMPB (O95630)
FGF-21 (Q9NSA1)
MCP-2 (P80075)
MCP-4 (Q99616)
4 6 8 10 12 14 16 18
Mean Decrease Accuracy
Predicted Group
Actual Group
Group ID | ART | HIVNC | Pre-ART | Class Error
ART | 46 | 0 | 3 | 0.13
HIVNC | 9 | 33 | 0 | 0.21
Pre-ART | 1 | 1 | 37 | 0.05
Predictive accuracy = 86.6%
b.
Row Z-Score
CD8A
CCL23
CCL19
CXCL10
SCF
CSF-1
IL18
MCP-2
TRAIL
CXCL11
CXCL9
CD5
TNFB
TRANCE
IL-12B
PD-L1
SLAMF1
LIF-R
IL10
ADA
CD244
TNFRSF9
CCL20
CX3CL1
CD6
MCP-3
NT-3
IL-15RA
c.
TRAIL,CST5,MMP-1,NT-3,ADA
HIVNC-ART (11)
PreART-ART (38)
PreART-HIVNC (31)
4E-BP1
1
5
5
4
0
24
2
CD8A
TRANCE
CD5
SLAMF1
CCL23
d.
Normalized protein expression (NPX)
*p<0.05
**p<0.001
CD8A
TRAIL
CST5
SLAMF1
MMP-1
TRANCE
CCL23
CD5
4E-BP1
NT-3
ADA
ART
HIVNC
Pre-ART